1. Home
  2. MYGN vs VVX Comparison

MYGN vs VVX Comparison

Compare MYGN & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • VVX
  • Stock Information
  • Founded
  • MYGN 1991
  • VVX 2014
  • Country
  • MYGN United States
  • VVX United States
  • Employees
  • MYGN N/A
  • VVX N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • VVX Diversified Commercial Services
  • Sector
  • MYGN Health Care
  • VVX Consumer Discretionary
  • Exchange
  • MYGN Nasdaq
  • VVX Nasdaq
  • Market Cap
  • MYGN 744.7M
  • VVX 1.4B
  • IPO Year
  • MYGN 1995
  • VVX 2014
  • Fundamental
  • Price
  • MYGN $5.65
  • VVX $49.45
  • Analyst Decision
  • MYGN Hold
  • VVX Buy
  • Analyst Count
  • MYGN 15
  • VVX 9
  • Target Price
  • MYGN $15.14
  • VVX $64.11
  • AVG Volume (30 Days)
  • MYGN 1.4M
  • VVX 246.0K
  • Earning Date
  • MYGN 08-05-2025
  • VVX 08-05-2025
  • Dividend Yield
  • MYGN N/A
  • VVX N/A
  • EPS Growth
  • MYGN N/A
  • VVX N/A
  • EPS
  • MYGN N/A
  • VVX 1.29
  • Revenue
  • MYGN $831,300,000.00
  • VVX $4,327,514,000.00
  • Revenue This Year
  • MYGN N/A
  • VVX $4.02
  • Revenue Next Year
  • MYGN $6.68
  • VVX $4.80
  • P/E Ratio
  • MYGN N/A
  • VVX $38.21
  • Revenue Growth
  • MYGN 7.38
  • VVX 7.38
  • 52 Week Low
  • MYGN $3.81
  • VVX $41.08
  • 52 Week High
  • MYGN $29.30
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 58.80
  • VVX 64.26
  • Support Level
  • MYGN $4.90
  • VVX $49.01
  • Resistance Level
  • MYGN $5.74
  • VVX $50.24
  • Average True Range (ATR)
  • MYGN 0.27
  • VVX 1.21
  • MACD
  • MYGN 0.07
  • VVX 0.41
  • Stochastic Oscillator
  • MYGN 90.82
  • VVX 86.29

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: